Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;92(6):522-527.
doi: 10.1007/s00104-021-01371-3. Epub 2021 Feb 23.

[Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer]

[Article in German]
Felix Gronau  1 , Maximilian Jara  1 , Linda Feldbrügge  1 , Vincent Wolf  1 , Alan Oeff  1 , Beate Rau  2   3
Affiliations
Review

[Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer]

[Article in German]
Felix Gronau et al. Chirurg. 2021 Jun.

Abstract
in English, German

Background: Gastric cancer with peritoneal metastases is associated with an extremely poor prognosis. Developed multimodal treatment concepts, which include a combination of perioperative systemic treatment and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), show promising results with respect to improvement of the long-term survival.

Methods: This article contains a review of the literature of published studies on the topic of gastric cancer and peritoneal metastasis.

Results: The prognosis of patients with gastric cancer peritoneal carcinomatosis shows an extremely limited median survival of 7 months under palliative second-line systemic treatment. The median survival time increased to 12 months with cytoreductive surgery and in combination with HIPEC showed a positive effect on survival in individual studies.

Expert opinion: Treatment recommendations for patients with peritoneal metastases of gastric cancer should be carried out by experts in surgical reference centers.

Zusammenfassung: HINTERGRUND: Das peritoneal metastasierte Magenkarzinom ist mit einer äußerst schlechten Prognose assoziiert. Entwickelte multimodale therapeutische Konzepte, welche eine Kombination aus perioperativer Systemtherapie und zytoreduktiver Chirurgie mit hyperthermer intraperitonealer Chemotherapie (HIPEC) beinhalten, zeigen Erfolg versprechende Ergebnisse hinsichtlich der Verbesserung des Langzeitüberlebens.

Methoden: Diese Arbeit beinhaltet eine Literaturrecherche zu publizierten Studien zum Thema Magenkarzinom und peritoneale Metastasierung.

Ergebnisse: Die Prognose des peritoneal metastasierten Magenkarzinoms ist mit einem medianen Überleben von nur 7 Monaten unter palliativer Zweitliniensystemtherapie äußerst limitiert. Eine zytoreduktive Chirurgie ermöglicht im Mittel ein medianes Überleben von 12 Monaten; eine zusätzliche HIPEC zeigte in einzelnen Studien gute Auswirkungen auf das Überleben.

Expertenmeinung: Behandlungsempfehlungen für Patienten mit peritoneal metastasiertem Magenkarzinom sollten durch Experten in chirurgischen Referenzzentren erfolgen.

Keywords: Cytoreduction; Hyperthermia; Intraperitoneal chemotherapy; Intraperitoneal metastasis; Morbidity.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

Literatur

Verwendete Literatur
    1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90 - PubMed - PMC
    1. Yonemura Y, Canbay E, Li Y et al (2016) A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol 42:1123–1131 - PubMed
    1. Saladino E, Fleres F, Mazzeo C et al (2014) The role of prophylactic hyperthermic intraperitoneal chemotherapy in the management of serosal involved gastric cancer. Anticancer Res 34:2019–2022 - PubMed
    1. Spiliotis J, Vaxevanidou A, Sergouniotis F, Lambropoulou E, Datsis A, Christopoulou A (2011) The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study. J BUON 16:74–79 - PubMed
    1. Desiderio J, Chao J, Melstrom L et al (2017) The 30-year experience—a meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer 79:1–14 - PubMed - PMC
Weiterführende Literatur
    1. Kelly KJ, Nash GM (2014) Peritoneal debulking/intraperitoneal chemotherapy-non-sarcoma. J Surg Oncol 109:14–22 - PubMed
    1. Goere D, Gras-Chaput N, Auperin A et al (2014) Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab. BMC Cancer 14:148 - PubMed - PMC
    1. Vanounou T, Garfinkle R (2016) Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin in the era of value-based medicine. Ann Surg Oncol 23:2556–2561 - PubMed
    1. Huo YR, Richards A, Liauw W, Morris DL (2015) Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol 41:1578–1589 - PubMed

MeSH terms

LinkOut - more resources